Product Launch | YHLO iBC 2000 Fully Automated Biochemistry Analyzer

On March 22, 2025, YHLO officially launched the iBC 2000 Fully Automated Biochemistry Analyzer on the opening day of CACLP in Hangzhou. Renowned experts in clinical laboratory medicine and YHLO executives gathered at the event to witness the impressive debut of this cutting-edge analyzer.

Professor Song Haibo (far left), Vice President of the National Association of Health Industry and Enterprise Management, President of the Medical Laboratory Industry Branch, Deputy Director of the Shanghai Institute of Experimental Medicine, Director of the Institute of In Vitro Diagnostics Industry Development, and Editor-in-Chief of VIEW Medicine;
Mr. Hu Kunhui (far right), Chairman and CEO of YHLO Group;
Professor Wang Baolong (second left), Director of the Laboratory Department at the First Affiliated Hospital of the University of Science and Technology of China, Vice Chairman of the Medical Laboratory Branch of the National Association of Health Industry and Enterprise Management, and Chairman of the Laboratory Medicine Branch of the Anhui Medical Association;
Professor Wang Hualiang (second right), President of the Shanghai Institute of Experimental Medicine, Chairman of the Medical Laboratory Branch of the National Association of Health Industry and Enterprise Management, and Editor-in-Chief of VIEW;
Professor Wang Shengjun (third left), Vice President of the Affiliated Hospital of Jiangsu University, Deputy Director of the Jiangsu Key Laboratory of Laboratory Medicine, and Chairman of the Microbiology and Immunology Branch of the Jiangsu Medical Association;
Mr. Haruhisa Watanabe (third right), President of YHLO Japan R&D Center;
Mr. Song Yongbo (fourth left), Vice Chairman and General Manager of YHLO Group;
Mr. Xiao Yujin (fourth right), Vice General Manager of YHLO Group and Chairman of Yacada.

Mr. Hu Kunhui, Chairman and CEO of YHLO, stated that YHLO has always been driven by technological innovation, with a strong commitment to research and development. By integrating self-developed instruments and reagents across multiple platforms, YHLO aims to deliver efficient and intelligent laboratory solutions. In the future, through innovations like the iBC 2000 and other Made-in-China technologies, YHLO will continue to create value for the global medical industry, demonstrating the company’s technical strength and social responsibility.

Mr. Haruhisa Watanabe, President of YHLO Japan R&D Center, emphasized that as an R&D expert, the launch of the iBC 2000 reflects the advantages of YHLO’s “dual-engine” R&D model. This achievement is the result of collaborative innovation between the Chinese and Japanese R&D teams. Looking ahead, these teams will continue to work together to deliver more exceptional products and solutions to support global healthcare.

The iBC 2000 achieves a single-unit throughput of up to 3200T/H and a maximum connected throughput of 9200T/H, providing efficient and precise testing capabilities that highlight the technological advancement of national brands. Its launch further strengthens YHLO’s biochemistry platform, covering the mid-to-high throughput segment. The analyzer can also integrate seamlessly with YHLO’s self-developed CLIA platform and total laboratory automation systems, offering users high-throughput, high-performance, and intelligent lab solutions. This product is expected to serve diverse clinical scenarios, addressing critical challenges in diagnostic testing.

During the event, YHLO’s multi-platform innovations attracted significant attention from experts, scholars, and industry professionals. To help interested attendees gain deeper insights, YHLO organized a series of mini-classes and product presentations, showcasing the unique features of its technologies. These included an in-depth analysis of the iTLA mini Pro Fully Automated Biochemistry-Immunology Line and a feature presentation on the iBC 2000 analyzer.

At the booth, interactive robot demonstrations became a major highlight. The robots introduced the advantages of YHLO iTLA Max system and engaged visitors through handshakes and interactive activities, enhancing the visitor experience and presenting product highlights in a more engaging and intuitive way.

In addition, the capsule toy activity attracted enthusiastic participation. The creative prizes, featuring Hangzhou’s local cultural elements, not only added enjoyment to the event but also reflected YHLO’s commitment to user engagement and experience.

Innovation is not only YHLO’s core competency but also the driving force behind its continuous progress. In the future, YHLO will remain focused on innovation-driven development, actively responding to China’s national strategy of “New Quality Productive Forces,” and delivering high-quality Made-in-China medical solutions to the global healthcare community.

Attachments:

None

From “Made in China” to International Recognition | iTLA Max Wins Another International Award

None

From “Made in China” to International Recognition | iTLA Max Wins Another International Award